Bertucci F., Finetti P., Simeone I., Hendrickx W., Wang E., Marincola F.M., Viens P., Mamessier E., Ceccarelli M., Birnbaum D., et al. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Br. J. Cancer. 2018;119:1383–1391. doi: 10.1038/s41416-018-0309-1. DOI: https://doi.org/10.1038/s41416-018-0309-1

Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–198. doi: 10.1158/2159-8290.CD-18-1177. DOI: https://doi.org/10.1158/2159-8290.CD-18-1177

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. DOI: https://doi.org/10.3322/caac.21492

Tao L., Chu L., Wang L.I., Moy L., Brammer M., Song C., Green M., Kurian A.W., Gomez S.L., Clarke C.A. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes Control. 2016;27:1127–1138. doi: 10.1007/s10552-016-0791-9. DOI: https://doi.org/10.1007/s10552-016-0791-9

Foukakis T., Fornander T., Lekberg T., Hellborg H., Adolfsson J., Bergh J. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res. Treat. 2011;130:553–560. doi: 10.1007/s10549-011-1594-z. DOI: https://doi.org/10.1007/s10549-011-1594-z

Criscitiello C, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treat Rev. 2016;50:205–207. doi: 10.1016/j.ctrv.2016.09.019. DOI: https://doi.org/10.1016/j.ctrv.2016.09.019

Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–867. doi: 10.1200/JCO.2011.41.0902. DOI: https://doi.org/10.1200/JCO.2011.41.0902

Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26:1698–1704. doi: 10.1093/annonc/mdv239. DOI: https://doi.org/10.1093/annonc/mdv239

Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019; 37(7):559–569. doi: 10.1200/JCO.18.01010. DOI: https://doi.org/10.1200/JCO.18.01010

Beckers RK, Selinger CI, Vilain R, et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69:25–34. doi: 10.1111/his.12904. DOI: https://doi.org/10.1111/his.12904

Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–370. doi: 10.1158/2326-6066.CIR-13-0127. DOI: https://doi.org/10.1158/2326-6066.CIR-13-0127

Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47:52–63. doi: 10.1016/j.humpath.2015.09.003. DOI: https://doi.org/10.1016/j.humpath.2015.09.003

Li X, Li M, Lian Z, et al. Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis. Target Oncol. 2016;11:753–761. doi: 10.1007/s11523-016-0451-8. DOI: https://doi.org/10.1007/s11523-016-0451-8

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84. DOI: https://doi.org/10.7326/M14-2385

Cochrane Effective Practice and Organisation of Care (EPOC). EPOC resources for review authors [Internet]. Oxford: Cochrane; 2017.

Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. DOI: https://doi.org/10.1016/j.jclinepi.2010.04.026

Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med [Internet]. 2005 May [cited 2018 Dec 3];37(5):360-3.

Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016; 34:2460–7. DOI: https://doi.org/10.1200/JCO.2015.64.8931

Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., Rosenberg S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–1544. doi: 10.1182/blood-2008-12-195792. DOI: https://doi.org/10.1182/blood-2008-12-195792

Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 2002;8:793–800. doi: 10.1038/nm730. DOI: https://doi.org/10.1038/nm730

Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., Sharpe A.H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009;206:3015–3029. doi: 10.1084/jem.20090847. DOI: https://doi.org/10.1084/jem.20090847

Loi S, Adams S, Schmid P, et al. LBA13 relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann Oncol. 2017;28(Suppl 5):mdx440.005. DOI: https://doi.org/10.1093/annonc/mdx440.005

Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase 2 KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404. DOI: https://doi.org/10.1093/annonc/mdy517

Tolaney S, Kalinsky K, Kaklamani V, et al. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Cancer Res. 2018;78(abstr):PD6–PD13. DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD6-13

Pizzuti L, Krasniqi E, Barchiesi G, et al. Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. J Cancer. 2019;10(24):5903‐5914. Published 2019 Oct 12. doi:10.7150/jca.35109. DOI: https://doi.org/10.7150/jca.35109

Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–86. DOI: https://doi.org/10.1007/s10549-017-4537-5

Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82. DOI: https://doi.org/10.1001/jamaoncol.2018.4224

Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21. DOI: https://doi.org/10.1056/NEJMoa1809615

Emens LA, Loi S, Rugo HS, et al. Abstract GS1-04: IMpassion130: efficacy in immune biomarker subgroups from phase III study of atezolizumab + nabpaclitaxel in patients with treatment-naïve, locally advanced or metastatic TNBC. Cancer Res 2019;79(4 Suppl):Abstract nr GS1 –04. DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS1-04

Aigner J, Marmé F, Smetanay K, et al. Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice. Anticancer Res. 2013;33:3407–3413.